Talnetant

Generic Name
Talnetant
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C25H22N2O2
CAS Number
174636-32-9
Unique Ingredient Identifier
CZ3T9T146K
Background

Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug for the treatment of schizophrenia.

Indication

Investigated for use/treatment in schizophrenia and schizoaffective disorders, irritable bowel syndrome (IBS), and chronic obstructive pulmonary disease (COPD).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

Phase 2
Completed
Conditions
Schizophrenia
First Posted Date
2006-03-10
Last Posted Date
2013-02-15
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
275
Registration Number
NCT00300963
Locations
🇺🇸

GSK Investigational Site, Richmond, Virginia, United States

Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia

First Posted Date
2005-02-15
Last Posted Date
2015-04-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
282
Registration Number
NCT00103727
Locations
🇺🇸

GSK Investigational Site, Richmond, Virginia, United States

Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

Phase 2
Completed
Conditions
Irritable Colon
First Posted Date
2005-01-19
Last Posted Date
2015-04-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
741
Registration Number
NCT00101985
Locations

GSK Investigational Site

Schizophrenia Study In Adults

Phase 2
Completed
Conditions
Schizophrenia
First Posted Date
2002-11-18
Last Posted Date
2017-08-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
231
Registration Number
NCT00049946
Locations
🇺🇸

GSK Clinical Trial Call Center, Terrell, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy